Publications by authors named "V G Kaklamani"
Genomic and transcriptomic landscape of HER2-low breast cancer.
Breast Cancer Res Treat
September 2024
Background: Novel agents have expanded the traditional HER2 definitions to include HER2-Low (HER2L) Breast Cancer (BC). We sought to evaluate the distinct molecular characteristics of HER2L BC to understand potential clinical/biologic factors driving resistance and clinical outcomes.
Methods: Retrospective analysis was performed on 13,613 BC samples, tested at Caris Life Sciences via NextGen DNA/RNA Sequencing.
Sacituzumab Govitecan (SG) is an antibody-drug conjugate that has demonstrated efficacy in patients with TROP-2 expressing epithelial cancers. In a xenograft model of intracranial breast cancer, SG inhibited tumor growth and increased mouse survival. We conducted a prospective window-of-opportunity trial (NCT03995706) at the University of Texas Health Science Center at San Antonio to examine the intra-tumoral concentrations and intracranial activity of SG in patients undergoing craniotomy for breast cancer with brain metastases (BCBM) or recurrent glioblastoma (rGBM).
View Article and Find Full Text PDFElacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
Clin Cancer Res
October 2024
Article Synopsis
- Elacestrant, a treatment for estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer, showed significantly longer progression-free survival (PFS) compared to standard endocrine therapy (SOC) for patients with ESR1 mutations who had previously received ET plus CDK4/6 inhibitors.
- In a phase III trial named EMERALD, patients were randomly assigned to receive either elacestrant or SOC, and the results indicated that those with ESR1 mutations and prior ET plus CDK4/6i usage of 12 months or more had a notably longer median PFS with elacestrant (8.6 months) versus SOC (1.9 months).
- The observed benefits of elacestrant
Article Synopsis
- The 21-gene recurrence score (RS) test, called Oncotype DX, helps decide if breast cancer patients need chemotherapy.
- Researchers studied over 10,000 women to see how well the RS works with other information like tumor size and patient age to predict cancer recurrence after treatment.
- They found that combining the RS with other factors gives much better predictions about whether the cancer will come back, especially between 5 to 10 years after diagnosis.